Back

MHRA Sets Out Strategy 2030 to Modernise UK Medicines Regulation

lite News Desk 2 min read

At a glance

  • MHRA published Strategy 2030 on 14 October 2026.
  • Plans include faster regulatory processes and new AI initiatives.
  • Strategy targets diversity, enforcement, and international collaboration.

The Medicines and Healthcare products Regulatory Agency (MHRA) released its Strategy 2030, outlining plans to update regulatory practices in response to advances in artificial intelligence, personalised medicines, and digital health. The document sets out the agency’s mission and procedural commitments for the coming years.

According to the published strategy, the MHRA aims to achieve “health and prosperity for all, through scientific excellence.” The strategy details a range of proposed actions intended to modernise the agency’s regulatory approach and support patient-centred outcomes.

One of the main commitments in the strategy is to accelerate regulatory timelines. The MHRA plans to reduce the time for its scientific advice service from 90 days to 45 days and to halve the initial assessment period for qualifying Phase 1 clinical trials to 14 days. These changes are intended to streamline processes for medicines and device approvals.

The strategy also includes several technology-focused initiatives. The MHRA intends to establish an AI-enabled Clinical Trial Protocol Checker, publish an AI Medicines Development Action Plan in 2027, and set up a Centre for AI and Digital Health. These measures are designed to address the growing role of artificial intelligence in healthcare innovation.

What the numbers show

  • Strategy 2030 was published on 14 October 2026.
  • Scientific advice service timeline to be reduced from 90 to 45 days.
  • Initial assessment for Phase 1 trials to be halved to 14 days.

The MHRA’s strategy also addresses patient engagement and diversity. It includes plans to increase diversity in clinical studies, launch a Women’s Health Plan, and update the Patient and Public Involvement and Engagement Plan. These steps are intended to ensure that regulatory decisions reflect a broad range of patient experiences and needs.

Enforcement is another focus area in the strategy. The MHRA has committed to increasing its criminal enforcement capacity to address illegal medicines and devices. The agency also plans to work with social media platforms and online marketplaces to prevent the distribution of harmful products to the public.

Support for innovation is outlined through proposals such as a voucher scheme for UK start-ups and small companies, encouragement of non-animal testing methods, and the development of a risk-proportionate framework for rare disease therapies. These initiatives are designed to foster a supportive environment for new medical technologies and treatments.

International collaboration is highlighted as a priority. The strategy includes plans to rely on trusted regulators, develop Regulatory Innovation Corridors, chair the Access Consortium, and hold an annual regulatory science conference. These efforts are aimed at strengthening the UK’s position in global regulatory science and cooperation.

* This article is based on publicly available information at the time of writing.

More from Health & Biotech

  1. An agreement was announced on October 12, 2026, appointing Axmed as a distributor for HIV medicines in over 50 countries, according to reports.

  2. A recent approval details Hovilpri's use for treating drug-resistant HSV lesions in immunocompromised adults, according to the regulator.

  3. A statement confirms the first imported Ebola case in Kenya on October 6, 2026. Meetings for public health staff were suspended, according to reports.

  4. New resources for patient-reported outcomes were added to the digital mental health collection on October 8, 2026, according to reports.

  5. The MHRA launched a Real-World Evidence guidance hub on October 9, 2026, to support regulatory decisions using real-world data, according to reports.